№ lp_1_2_22007
File format: docx Character count: 29142 File size: 82 KB
Version: 2.0
Year: 2025
Region / city: [location/service/organisation]
Topic: Urinary Tract Infection, Nitrofurantoin, PGD (Patient Group Direction)
Document type: PGD (Patient Group Direction)
Organization: UKHSA
Author: Dr. Diane Ashiru-Oredope, Dr. Imran Jawaid, Dr. Kiren Collison, Dr. Naomi Fleming, Mandy Slatter, Jo Jenkins, Kieran Reynolds, Liz Cross, Professor Bhaskar Somani, Temitope Odetunde, Tracy Rogers
Target audience: Registered healthcare professionals authorized by their organization
Effective date: 1st January 2026
Review date: 30th June 2028
Expiry date: 31st December 2028
Approval body: UKHSA HCAI & AMR Division
Document version history: 1.0 (January 2023), 1.1 (July 2023), 1.2 (February 2024), 1.3 (April 2024), 1.4 (January 2025), 2.0 (October 2025)
PGD reviewed by: National UTI antimicrobial PGD Short Life Working Group
Context: This document outlines a Patient Group Direction for the use of nitrofurantoin in the treatment of urinary tract infections, specifying authorized practitioners and legal requirements.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Community Pharmacy Urinary Tract Infection Service Patient Group Directions for the supply of nitrofurantoin or trimethoprim in [insert local health board name]
Year: 2024
Region / City: Wales
Topic: Healthcare, Pharmacy, Urinary Tract Infection
Document Type: Patient Group Directions (PGD)
Organisation: Welsh Medicines Advice Service, NHS Wales
Author: Dianne Burnett, Louise Allen, Emlyn Pritchard, Adam Mackridge, Richard Coulthard
Target Audience: Healthcare professionals, community pharmacists
Validity Period: From 03 June 2024 to 02 June 2027
Approval Date: 22 April 2024
Ratification Date: 09 May 2024
Review Date: 08 February 2027
Expiry Date: 02 June 2027
Version: 1.0
Change History: Version 1.0 developed on 22 December 2023
Clinical Condition: Acute, uncomplicated lower urinary tract infection
Treatment: Nitrofurantoin, Trimethoprim
Applicable Group: Non-pregnant females or transgender males (16-64 years)
Authorising Organisation: Local Health Board
Staff Requirements: Registered pharmacists, authorised by name
Retention Period: 8 years for adults, 25 years for children
Local Inquiries: [insert local details]
A Prospective Study on the Safety, Efficacy, and Cost-Effectiveness of Nitrofurantoin for Urinary Tract Infections in Pregnancy
Year: 2024
Region / City: Not specified
Topic: Safety, efficacy, cost-effectiveness of nitrofurantoin in pregnancy
Document Type: Research article
Organization / Institution: Journal of Advances in Medicine and Medical Research
Author: DR (Created by), PM (Checked by), MBM (Approved by)
Target Audience: Scientific community, healthcare professionals
Period of validity: Not specified
Approval Date: 07-07-2024
Date of Changes: Not specified
Ethical Issues: Not specified
Keywords: Nitrofurantoin, pregnancy, urinary tract infections, cost-effectiveness, safety, efficacy
Language: English
Sample Size: 180 participants
Study Design: Single-center study
Limitations: Single-center design, no control group, lack of G6PD screening, small sample size, no long-term follow-up of neonatal outcomes
Contextual Description: Research article exploring the safety, efficacy, and cost-effectiveness of nitrofurantoin for urinary tract infections in pregnancy, highlighting various study limitations and areas for future research.
Intrapartum administration of benzylpenicillin sodium for prevention of early-onset Group B Streptococcus (GBS) infection in neonates in [location/service/organisation]
Year: 2025
Region / City: [location/service/organisation]
Topic: Intrapartum administration of benzylpenicillin for GBS prevention
Document Type: Patient Group Direction (PGD)
Organisation: [organisation]
Author: Amy Moore, Christina Nurmahi, Emma Luhr, Felipe Castro Cardona, George Attilakos, Hannah Putley, Janine Elson, Jo Jenkins, Rosie Furner, Sandy Richards, Trixie McAree, Verena Wallace, William Rial, Zoë van Zuylen
Target Audience: Registered healthcare professionals authorised to practice under PGD
Period of Validity: 1st January 2026 - 31st December 2028
Approval Date: 1st January 2026
Review Date: 1st June 2028
Expiry Date: 31st December 2028
Change History: Version 1.0 - January 2023, Version 2.0 - July 2025
Context: This document is a formal guideline for registered healthcare professionals on the use of benzylpenicillin sodium to prevent early-onset GBS infection in neonates.
Patient Group Direction for Supply of Progestogen-Only Contraceptive Pill (POP) in [location/service/organisation], Version 3.0, October 2025
Year: 2025
Region / Location: [location/service/organisation]
Document Type: Patient Group Direction (PGD)
Issuing Organization: College of Sexual and Reproductive Healthcare (CoSRH)
Authors / Contributors: Alison Crompton, Bola Sotubo, Carmel Lloyd, Dr Cindy Farmer, Clare Livingstone, Dipti Patel, Emma Anderson, Heather Randle, Julia Hogan, Kate Devonport, Kirsty Armstrong, Lisa Knight, Michelle Jenkins, Portia Jackson, Rachel Logan, Tanya Lane, Jo Jenkins, Kieran Reynolds, Rosie Furner, Sandra Wolper
Intended Users: Registered healthcare professionals authorized to operate under the PGD
Implementation Date: 1st April 2026
Review Date: 1st September 2028
Expiry Date: 31st March 2029
Version History: Version 1 (April 2020), Version 1.1 (November 2020), Version 2.0 (April 2023), Version 2.1 (April 2024), Version 2.2 (April 2025), Version 2.3 (July 2025), Version 3.0 (October 2025)
Regulatory Reference: Human Medicines Regulation 2012, Schedule 16 Part 4
Approval: College of Sexual and Reproductive Healthcare (CoSRH), January 2026
Supporting Groups: Reproductive Health PGDs Short Life Working Group (SLWG)
Contextual Scope: Contraceptive medicine administration and patient safety guidelines
Topics: capsulestablets nitrofurantoin locationserviceorganisation